Repligen PE ratio RGEN

Share price divided by earnings per share over the last twelve months, since 2012.

Today, Oct 23, 2026: 242×
10-year median: 120×
Against its 10-year history: 89th; percentile: 0 is its lowest day, 100 its highest
10-year range: 46.7× to 495×
Peer median: 29.3×

Repligen's PE ratio is 242× as of Oct 23, 2026: a share price of $176.93 against $0.73 of earnings per share over the last twelve months.

That is above its ten-year median of 120×, higher than on 89% of days in the last ten years.

Over that time it ranged from 46.7× in Apr 2023 to 495× in Jul 2024.

The median for 10 biotech stocks of a similar size is 29.3×.

PE ratio over time

median 120.1×

The dashed line is the 10-year median and the shaded band the middle half of its days.

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	242×	114×	260×
2025	n/m a value too high to mean anything
2024	495×	84.5×	495×
2023	88.6×	46.7×	90.0×
2022	58.4×	56.3×	98.5×
2021	126×	118×	276×
2020	234×	189×	312×
2019	188×	99.7×	206×
2018	101×	48.5×	133×
2017	61.5×	56.6×	166×
2016	154×	77.9×	169×
2015	105×	55.8×	201×
2014	56.2×	18.1×	64.7×
2013	18.3×	14.4×	88.8×
2012	76.0×	68.5×	150×

Against its peers

Companies in Biotechnology nearest Repligen's size, closest first, today.

Company	PE ratio
RGENRepligen	242×
KRYSKrystal Biotech	39.0×
TECHBIO-TECHNE	63.1×
HALOHalozyme Therapeutics	37.5×
NBIXNeurocrine Biosciences	20.9×
EXELExelixis	20.3×
INCYIncyte	14.7×
UTHRUnited Therapeutics	21.0×
ALNYAlnylam Pharmaceuticals	37.8×
ADMAAdma Biologics	15.3×
ONCBeOne Medicines	67.6×
Peer median	29.3×

Where Repligen ranks

#16of 16Biotech stocks with the lowest PE ratio

What the PE ratio tells you

Share price divided by earnings per share over the last twelve months. It is the price tag on a dollar of profit: 20× means you pay $20 for $1 of yearly earnings.

Blank while earnings are negative. A very low PE can mean the market expects profits to fall, so read it with growth and the company's own history.

More on Repligen

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.